Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIOLA
NCT05340413Phase 2Completed
- Sponsor
- SOLTI
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in breast cancer, sponsored by SOLTI. Started Mar 2022; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05340413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05340413.